Menu

Next-Gen Sequencing User Survey

Outsourcing is still the rule and data analysis, the bottleneck.

Nov 1, 2014
Christi Bird

In May, The Scientist, in collaboration with Frost & Sullivan, an international market intelligence and consulting firm, conducted a brief survey of our readers about their use of next-generation sequencing (NGS) technology. The majority of NGS work is focused on disease-related and basic research. While only 40% of respondents perform in-house NGS, that percentage is expected to increase by 4% in the next year. Half of those surveyed plan to perform RNA-Seq in the next two years. The most significant bottleneck in NGS workflow is the length of time spent analyzing and interpreting data, with 32% of the respondents outsourcing the work to in-house bioinformatics colleagues or third-party companies.
—Christi Bird, Senior Industry Analyst, Life Sciences, Frost & Sullivan

All figures are rounded

 

TIME ALLOTMENT: The most significant bottleneck in NGS workflow is the length of time spent analyzing data. A quarter of researchers surveyed report that performing NGS data analysis requires more than a week, while 32% of the respondents outsource this task to their organizations’ bioinformatics group or to a third party. (Global, 2014)PURCHASER CONCERNS: Data accuracy and operating costs are the top criteria when purchasing sequencing instruments. However, if data accuracy is equal between two instruments, operating cost, breadth of applications, read length, and throughput assume greater importance in the purchasing decision. (Global, 2014)

NGS SOFTWARE ANALYSIS BUDGETS: In-house annual budgets for NGS data-interpretation software are more than double the amount spent by those who outsource. While the overall average budget for NGS software is approximately $8,500, this figure masks the dramatic differences between in-house (from $13,000 to $14,000) and outsourced (from $4,500 to $6,300) NGS data analysis. (Interpolated Mean Scores) (Global, 2014)

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.